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Abstract
Background: Published methods for assessing remission in schizophrenia are variable and none
have been definitively validated or standardized. Andreasen et al (2005) suggest systematic
operational criteria using eight PANSS items for which patients must score ≤ 3 (mild) for at least
six months.
Methods: Using data from a one year, multi-site clinical trial (n = 675) remission criteria were
compared to total PANSS scores and other endpoints and demonstrate excellent agreement with
overall clinical status.
Results: Compared to total PANSS score of 60 points and other criteria, at time points > 6
months (8 and 12 months) the specificity of the remission criteria was 85%, i.e. of the patients who
had a total score >60, 85% were classified as "not in remission." Sensitivity was also very high; 75%
of patients with scores of <60 were classified as "in remission."Patients who dropped out of the
trial were more likely not to be in remission prior to dropping out.
Conclusion: These findings indicate that the remission criteria are both sensitive and specific
indicators of clinical status. Additional analyses are required to determine if remission status
predicts other outcomes, such as employment, independent living, and prognosis.
Background
Prevention and recovery for patients with schizophrenia
and other psychotic disorders are becoming the principle
objectives for research and treatment. [1] While promising
findings suggest that these goals will soon be attainable,
efforts have also focused on development of interventions
intended to reduce symptom severity over time. By main-
taining low levels of psychopathology, such interventions
may promote productive social and occupational pursuits
and help contribute to the ultimate goal of recovery from
illness. Consequently, researchers and clinicians have
begun to seek consensus on the concept of symptom
remission. Current methods for assessing remission vary
from study to study, often utilizing measures of symptom
severity developed for other purposes. In the past, remis-
sion in schizophrenia has been measured either by
improvements in overall psychopathology from baseline
(as measured by statistically significant percentage reduc-
tions in all thirty Positive and Negative Syndrome Scale
(PANSS) items) or by reduction below specific threshold
levels (e.g.: scores of less than 3, Mild in all thirty PANSS
items). [2,3]
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While it makes intuitive sense to utilize instruments that
are well characterized in clinical research, none have been
definitively validated as measures of remission. Addition-
ally, when used according to current standards, some
interview tools (e.g. the Structured Clinical Interview for
the PANSS or SCI-PANSS) require extensive time to com-
plete as they incorporate a number of questions and
probes that may not be useful for assessing remission. The
process of developing and testing a measure of remission
based on threshold levels of selected PANSS items should
be differentiated from previous efforts to create shortened
versions of existing scales (e.g. the SF-12, derived from the
SF-36). Rather than substitute for the 30-item PANSS,
development of a concise outcome measure for remission
in schizophrenia would create a benchmark for treatment
and maintenance goals in clinical research and general
practice. By developing an approach based on uniform
criteria rather than the various criteria currently in use, a
more meaningful standard for assessing remission status
can be applied in both research and clinical practice.
The Remission Construct
Early in 2005, Andreasen et al published an article in the
American Journal of Psychiatry on strategies to define
remission in schizophrenia through succinct operational
criteria using threshold levels maintained over time.
Through review of previous work and historically
accepted constructs, Andreasen et al identified three pri-
mary areas of concern – Psychoticism, Disorganization,
and Negative Symptoms (Psychomotor Poverty). These
were then related to DSM criteria and finally to specific
items from various psychometric instruments. Eight
PANSS items (see Table 1) based on this framework were
identified. The authors suggested that in order to qualify
for remission status, patients must score less than or equal
to 3 (mild) on these eight items. This must be maintained
for at least six months. Remission was also described as
"indicating progress towards recovery" associated with
sufficiently low levels of psychopathology such that
behavior is no longer markedly affected. A number of
publications have come out in support of this construct
(van Os et al 2006), including an important report by
Docherty et al. (2007) showing that the remission criteria
was associated with low CGI scores and improvements in
patient reported outcomes.[4,5]
Symptomatic and Functional Remission
Weiden et al. suggest that functional endpoints are not
independent from psychopathology, describing sympto-
matic "stabilization" as a prerequisite for improvements
in cognition, quality of life, and related areas. [6] Support-
ing evidence from the literature shows that specific aspects
of psychopathology seem to be related to occupational
function. Some reviews of the subject have critiqued psy-
chometric rating scales for their failure to incorporate
functional outcomes. This is a valid concern and one that
requires additional attention and development. However,
several instruments do take the impact of symptoms on
function into account, such as the PANSS. While most of
the PANSS items that are included in Table 1 are made
largely on the basis of clinical observation, three are also
based in part on functional impact over the past week. A
fourth item (Passive/apathetic social withdrawal) is based
solely on informant report of impairments in social func-
tion. Although these items may not provide a thorough
indication of functional status, if utilized correctly, they
should provide some evidence of the impact of disease
severity on progress towards functional remission.
Psychometric Properties of PANSS Remission Items
In an effort to determine how to group PANSS items in
meaningful ways beyond the conceptually derived Posi-
tive, Negative, and General Psychopathology subscales,
several rigorous factor analytic approaches have been
applied to large PANSS datasets. PANSS remission items
may be considered according to their factor loadings.
Using the PANSS "Pentagonal Model" loadings of White
et al (1997) and the six-factor solution of van den Oord et
al. (2005) the eight Remission items account for the high-
est loading items in the Positive, Negative, and Disorgan-
ized factors (P1 and G9, N6 and N1, respectively) as well
as a number of the additional high to moderately loading
items in the Withdrawal, and Autistic Preoccupation fac-
tors (see Table 2). [7,8]
Recently, researchers have conducted retrospective analy-
ses using these new remission criteria to determine
whether remission may be used as a study outcome. Lasser
et al (2005), as well as Sethuraman et al (2005) and others
have used the eight PANSS items selected by Andreasen et
al to identify remitted patients within randomized clinical
trials and characterize symptom severity and other fea-
tures.[9] Results show that remitted patients had lower
total PANSS scores, spent fewer days as inpatients, had
shorter duration of illness, and used fewer prescription
psychotropics.
Table 1: PANSS Items for use in Symptoms of Remission
Name Item # Sources of Information
Delusions P1 Interview & Informant Report
Unusual thought content G9 Interview Only
Hallucinatory behavior P3 Interview & Informant Report
Conceptual disorganization P2 Interview Only
Mannerisms/Posturing G5 Interview & Informant Report
Blunted affect N1 Interview Only
Passive social withdrawal N4 Informant Report Only
Lack of spontaneity/Flow of 
Conversation
N6 Interview Only
PANSS Remission items and sources of information.BMC Psychiatry 2007, 7:35 http://www.biomedcentral.com/1471-244X/7/35
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The studies published to date have provided valuable
insight into the promise of objective, standardized
approaches to assessment of remission status. However,
there are several outstanding questions that cannot be
readily addressed without additional work. The first ques-
tion is whether any consensus measure reliably identifies
patients who have low levels of psychopathology. Stand-
ard statistical tests, such as sensitivity and specificity,
agreement over chance, and positive predictive value must
be conducted. The second question is whether the longi-
tudinal criteria recommended by Andreasen and col-
leagues (i.e. maintaining low levels of psychopathology
for 6 months or more) improves the validity of the meas-
ure.
Methods
The PANSS is a thirty item scale, with individual item
scores from 1–7. Total scores range from 30–210. Using
PANSS data from a prospective, multi-site trial, symptom
severity was compared in patients in remission vs. those
not in remission as defined by the operational criteria
described above (scores ≤ 3 for all eight remission items).
Based on work by Leucht and others, two sets of cutoffs,
one for a "mildly ill" total PANSS Score (≤ 60) and a mod-
erately low total PANSS Score (≤ 75) were used as the
"gold-standards" in this analysis. [10] The analysis was
first conducted in cross-sectional fashion at each visit,
comparing total PANSS scores in subjects who meet
symptom severity criteria for remission vs. non-remitted
subjects.
Data from a previously published randomized clinical
trial (ROSE Study, described below) was analyzed longi-
tudinally through 4-month, 8-month, and one-year time
points in subjects who meet symptom severity and time-
frame criteria for remission vs. non-remitted subjects. In
this analysis, remission criteria were compared in both
cross-sectional fashion (determining remission status at a
single time point based solely on symptom severity) and
also using the longitudinal requirements, i.e. defining
remission based on prior status over time. For example,
remission status at 8 months was established using data
from 4- and 8-month visits and remission at 1 year was
established using data from 4 months through 8-months
for the same subjects. Using the described threshold for
symptom severity levels with further restriction to those
who also meet longitudinal requirements, subjects were
grouped according to the classifications shown in Table 3.
This allowed both cross-sectional and longitudinal
approaches to be compared.
Based on the cells identified in Table 3, analyses of four
parameters were calculated: sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value.
Logistic regression techniques were also be used to calcu-
late likelihood of remission status over time (with past
Table 3: Classification for Measures of Agreement
Low/Moderate (≤ 75), Low (≤ 60) Symptom 
Severity
High Symptom Severity Totals
In Remission a. In remission, low/moderate, low symptom 
severity
b. In remission, high symptom severity a + b. Total in Remission
Not In Remission c. Not in remission, low/moderate, low 
symptom severity
d. Not in remission, high symptom severity c +d. Total Not in Remission
Totals a + c. Total Low/Moderate Low Symptom 
Severity
b + d. Total High Symptom Severity Combined Totals
Remission vs. Symptom Severity Definitions.
Table 2: Psychometric Properties of PANSS Remission Items
Item # Sources of Information
P1 Highest loading item for Pentagonal (0.89) and Hexagonal Positive Factor (0.81)
G9 2nd highest loading item for Pentagonal (0.79) and Hexagonal Positive Factor (0.68)
P3 Primary loading on Pentagonal Positive Factor (0.43) and Hexagonal Positive Factor (0.28) Secondary on Pentagonal Autistic 
Preoccupation Factor (0.31)
N6 Highest loading item for Pentagonal (0.84) and Hexagonal Negative Factor (0.75)
N1 2nd highest loading item for Pentagonal Negative Factor (0.78) and Hexagonal Positive Factor (0.65)
N4 High loading on Pentagonal Negative Factor (0.689) and Hexagonal Withdrawal Factor (0.89)
G5 Moderate loading on Pentagonal Negative Factor (0.44) and Hexagonal Disorganized Factor (0.28)
P2 Highest loading on Pentagonal (0.74) and Hexagonal Disorganized Factor (0.75)
Loadings for PANSS remission items in factor-analysis derived modelsBMC Psychiatry 2007, 7:35 http://www.biomedcentral.com/1471-244X/7/35
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remission status used to predict remission status at a spe-
cific time point).
The ROSE Study
This analysis is based on data collected from the ROSE
Study, a one-year multi-center, open-label, randomized
clinical trial carried out in 21 centers in 17 US states (Mah-
moud et al, 1999). Patients were randomly assigned to
treatment with either risperidone or a conventional antip-
sychotic drug (n = 684). Follow-up was conducted from
1995–1997. [11]
Inclusion criteria for the study included patients aged 18–
60 y.o., diagnosed with schizophrenia or schizoaffective
disorder according to ICD-9-CM criteria. For inclusion,
diagnosis had to be made prior to age 35 with at least one
hospitalization in a locked facility in the 2-years prior to
the study, with symptom relapse at study start as defined
by either (a) an inpatient admission with a mental disor-
der within 10 days of study start-up or (b) an emergency
room visit, contact with crisis psychiatric treatment serv-
ices, or (c) an unscheduled office or clinic visit accompa-
nied by exacerbation of symptoms of schizophrenia. The
PANSS was administered every 4 months, i.e. at baseline
(T1), at 4 months (T2), at 8 months (T3), and at 12
months (T4).
Demographics
A majority (69%) of the patients in this study were male.
Average age was 38.5 y.o. (SD = 9), with 59.7% of subjects
identified as White, 26.5% Black, 4.7% Hispanic, 4.6%
Asian, and 4.4% in other categories. Mean age of onset of
psychiatric symptoms was 22 y.o. (SD = 6), making the
mean course of illness 16 years by the start of the study.
The majority of subjects had never been married at the
time the study was conducted (58.8%) and were inpa-
tients (65.5%).
Results
A correlation matrix between the 8-item remission scale
and total PANSS scores revealed negative and significant
relationships at the p < .001 level at all four time points.
Oneway ANOVA procedures demonstrate that the remis-
sion subscale scores explained a significant amount of the
variance in positive, negative, general and total PANSS
scores at T2 (four months), T3 (eight months) and T4
(one year), although not at T1 (baseline). Scores were sig-
nificantly lower for remitted subjects at all each of these
three follow-up visits (see Table 4). All between-group dif-
ferences were statistically significant (p < 0.001(.
At T1, when all subjects were in relapse according to ROSE
study definitions as described above, the 8-item criteria
correctly identified almost all (647 of 667) as not in
remission. If 'disease' is classified as study-defined relapse
and compared to the 8-item remission measure, then sen-
sitivity = .97 (647/667), specificity = 1.00 (0/0), positive
predictive value = 1.00 (647/647), and negative predictive
value = 0 (0/20) The PANSS total score was used to define
two cutoffs of 60 and 75 (see Tables 5 &6). For T2-T4, 70–
73% of those with a total PANSS score of less than 60 met
the remission criteria as compared with 51–52% of sub-
jects with total scores of less than 75. At each successive
visit from T2-T4, the positive predictive value of the remis-
sion criteria vs. a total PANSS score < 60 increases by
approximately 10%, going from 60% at T2, to 70% at T3
and 80% at T4 while remaining consistently high (95%–
98%) as compared to a total PANSS score < 75.
Longitudinal Findings
Although positive correlations were seen when T1 remis-
sion scores were compared to T2, T3 or T4, these associa-
tions were not statistically significant. However, all
associations between T2, T3 and T4 scores were signifi-
cantly correlated (p < .001; r's ranged from 0.39-.4.8).
When measured across all four timepoints, correlations
between the Positive subscale (0.3–0.65), Negative sub-
scale (0.41–0.66), and General Psychopathology subscale
(0.30–0.60) were significantly correlated (p < 0.001).
Predicting Remission Status
Logistic regression models were fit in order to calculate the
likelihood of maintaining remission based on status at
prior visits (see Table 7). Status at two consecutive visits
Table 4: Total PANSS Scores for Patients by Remission Status, T2-T4
N Mean Std. Deviation Std. Error
4 Month Visit (T2) Not In Remission 398 81.02 17.47 .875
In Remission 162 55.81 11.65 .915
Total 560 73.73 19.66 .831
8 Month Visit (T3) Not In Remission 335 76.77 16.95 .926
In Remission 180 53.57 10.92 .814
Total 515 68.66 18.73 .825
12 Month Visit (T4) Not In Remission 261 75.06 17.13 1.060
In Remission 166 51.77 11.19 .869
Total 427 66.01 18.89 .914
Mean total scores for study subjects, grouped according to remission status from T2-T4.BMC Psychiatry 2007, 7:35 http://www.biomedcentral.com/1471-244X/7/35
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was used to predict the status at the third visit. For subjects
w i t h  c o m p l e t e  P A N S S  d a t a  a t  T 3  ( N  =  5 1 5 ) ,  b e i n g  i n
remission at both T1 and T2 demonstrated a trend
towards prediction of remission at T3 (p = .064) with an
Odds Ratio = 4.8 (95% Confidence Interval: 0.91–24.8)
For subjects with complete PANSS data at T4 (N = 427),
being in remission at both T2 and T3 was a highly signifi-
cant predictor of remission at T4 (p < 0.001) OR = 9.7
(95% Confidence Interval: 5.4–17.4).
Dropouts
Analysis of subjects who dropped out of the study at T2-
T4 demonstrated a tendency not to be in remission at one
or more visits. Of the 71 dropouts at T3, 38 were not in
remission at T2, and only 13 were in remission at T2. A
Chi-Square test of this likelihood was significant at the p
< 0.001 level. The estimated Odds Ratio for dropping out
of the study given failure to achieve remission at the prior
visit is 7.3 for T3 (95% Confidence Interval: 4.7–11.2)
and 8.8 at T4 for subjects not in remission at prior visit
(95% Confidence Interval: 5.6–13.9). (See Table 8.)
Discussion
While a consensus is developing on one definition of
symptom remission, it is important to not confuse this
operational definition with the broader concept of recov-
ery. As described by Resnick and others, recovery is multi-
dimensional; reduction of psychotic symptoms represents
just one aspect of recovery. This difference is clearly artic-
ulated by in studies that use both objective clinical data,
as well as subjective endpoints such as patient self-experi-
ence and measures of hopefulness. Work by Lysaker and
colleagues demonstrates that the objective and subjective
elements of recovery are related, but (Lysaker et al., 2006)
Our analysis was intended to test the statistical properties
of one operational definition, based on previously pub-
lished criteria.
Based on our findings, the remission criteria of Andreasen
et al appear to be potentially valuable for future studies.
First, these criteria demonstrate high specificity, sensitiv-
ity, and positive predictive value when compared to
PANSS total score. The results of cross-sectional compari-
sons of two cut-offs of the total PANSS score (60 and 75)
clearly show almost all subjects identified as being in
remission at a given time point have low/low-moderate
levels of psychopathology. At first glance, the results of
this analysis at T1 (baseline visit) suggest that the remis-
sion criteria are not valid. However, it should be noted
that very few subjects met the remission criteria at base-
line (n = 30), making it difficult to draw any meaningful
conclusions regarding total PANSS scores. By contrast,
when study-defined relapse is examined, the remission
criteria appear to have excellent predictive value.
Next, when longitudinal components of the criteria are
included, the predictive value of the criteria improves.
Specifically, using data from T2-T4, for subjects in remis-
sion at 4 months and 8 months, the likelihood of being in
remission at 12 months is increased 10-fold versus those
subjects who fail to be in remission at one or both of the
preceding time points. The analysis of data from T1-T3 is
problematic since exceptionally few subjects met criteria
at T1, as noted previously. This may account in part for the
trend towards significance and the wide confidence inter-
val. The differences in the value of the remission criteria at
T3 to T4 are only observable when available data from
previous visits are included.
An interesting, if unexpected finding was the strong rela-
tionship between failure to achieve remission and risk of
dropping out of the study. Similar results have been
reported previously; Hatta et al. suggest that "treatment
resistance" may be predicted using PANSS baseline scores
on selected items, while other studies relate medication
non-compliance to PANSS-measured mood symptoms
and PANSS total score. [11-13] Through quantitative
approaches to treatment (i.e. "targeted treatment" – see
Opler et al., 2006 for a review) such findings are gradually
being applied in various clinical settings. In future
research, efforts might be made to study the reasons for
medication discontinuation and correlations with psy-
chopathology. [14]
Limitations
One of the major criticisms of analyses based on samples
drawn from randomized clinical trials is that they may not
resemble the general population. Certain types of subjects
are potentially excluded or under-represented (e.g. the
Table 6: 8-Item Remission Criteria vs. PANSS < 75
Visit n Sensitivity Specificity PPV
T1 636 .09 .995 .90
T2 560 .51 .97 .95
T3 515 .51 .98 .98
T4 427 .52 .95 .96
Mean 535 .44 .98 .96
Sensitivity, specificity, and PPV of the Remission criteria as compared 
to a total score <75.
Table 5: 8-Item Remission Criteria vs. Total PANSS Score < 60
Visit n Sensitivity Specificity PPV
T1 636 .27 .99 .60
T2 560 .72 .85 .61
T3 515 .70 .83 .69
T4 427 .73 .86 .79
Mean 535 .68 .90 .69
Sensitivity, specificity, and PPV of the Remission criteria as compared 
to a total score <60.BMC Psychiatry 2007, 7:35 http://www.biomedcentral.com/1471-244X/7/35
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elderly, those with co-morbid conditions, such as drug
dependence). [15] In order to test the validity of the
remission construct, particularly the extent to which it is
generalizable to all patients with schizophrenia spectrum
disorders, samples drawn from multiple populations
should be compared.
The primary limitation of this analysis is that it does not
incorporate an independent measure of functional status.
While there is some data showing that changes in PANSS
scores are related to quality of life measures, determining
the best approach towards quantifying remission will
require that both psychopathology and function be taken
into account. [16] Although not generally acknowledged,
the PANSS and similar scales are intended to incorporate
both observed and reported impact of symptoms on func-
tion. In patients suffering from acute psychosis, the lack of
insight necessitates the use of 'informants', or third-parties
who can contribute data on the patient's behavior and
activities over the past week. (Note: The clinician perform-
ing the interview is permitted to act as the informant if he
or she has specific knowledge about the patient over the
past week.) [17] While the conventions of the PANSS
require that informant data be obtained and incorpo-
rated, it is rarely considered separately from the scale
itself. In future research, informant data might be ana-
lyzed separately and jointly in the interest of determining
whether a meaningful "functional impact factor" could be
extracted from PANSS data, compared to independent,
previously validated measures and potentially applied to
new studies of remission in schizophrenia.
While the eight items included in this construct are posi-
tively associated with selected outcomes and have several
useful properties, it is necessary to take an empirical
approach to this question as well, i.e. utilizing statistical
techniques to objectively determine which PANSS items
are most strongly associated with remission over time.
One possibility is the application of Item Response The-
ory to determine which PANSS items are most valuable
for differentiating remitted and non-remitted patients;
such approaches have been taken with depression rating
scales. [19]
A practical concern is the need for standardized, efficient
methods for data collection.
Conclusion
In conclusion, our findings suggest that the operational
criteria outlined by Andreasen and colleagues have poten-
tial for use in the future. However, we also conclude that
our results are limited in several respects and key end-
points must be incorporated in future studies. Going for-
ward, we intend to compare multiple operational criteria
objectively, using rigorous techniques. In doing so, symp-
tom remission should be considered as one aspect of the
broader construct of recovery from illness – while future
studies may incorporate symptom remission as one aspect
of recovery (or possibly as one milestone in the process of
recovery) the field must continue to strive for the best pos-
sible outcomes for our patients. Given the urgent need to
continue to improve on "real-world" efficacy of antipsy-
chotic treatment [20], no construct should be considered
sacred and expectations should not be lowered based on
limited data.
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